Lancet HIV

Article	Citations
Transplant donation without discrimination	199
How do we prevent anal cancer in people living with HIV?	192
Lung cancer in people living with HIV	156
Argentina updates HIV laws	133
Evidence supports use of on-demand PrEP for HIV prevention	128
How much could long-acting PrEP cost in South Africa?	126
The Australian AIDS crisis through the eyes of volunteers	125
Are we ready for long-acting HIV treatment for adolescents?	122
Correction to Lancet HIV 2022; 9: e791–800	120
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	108
Lenacapavir: an attractive option, but proceed with caution	107
The time to end the war on drugs is long overdue	94
Risk estimation in HIV reveals our usual blind spots	91
Steps toward quick and equitable roll-out of lenacapavir	87
Optimising anal cancer screening through risk stratification	86
HIV and COVID-19: juxtaposition of two pandemics	84
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	80
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	77
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	77
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	76
Controversial chronicler of LGBTQ rights	68
Redefining care: injectable HIV treatment for adolescents	63
All roads lead to Westminster: the infected blood scandal	62
Unheard testimony	57
Gains and gaps: addressing HIV in diverse sex worker groups	55

Fate of people with HIV in jeopardy in Ukraine	55
Stigma reduction is key to improving the HIV care continuum	52
Game-changing study of second-line HIV treatment	51
A public health approach to drug use crucial to ending AIDS	50
Integration of sexual health and HIV services	50
Recent gay Black history in the UK	49
Reducing HIV transmission in British Columbia, Canada	49
Variations in the characteristics and outcomes of children living with HIV following universal ART in sub-Saharan Africa (2006–17): a retrospective cohort study	47
More evidence for worse COVID-19 outcomes in people with HIV	46
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	45
Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study	44
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	43
Need for transgender-specific data from Asia	43
Equitable access to long-acting PrEP on the way?	43
Sex as a biological variable in HIV-1 and schistosome co-infection	41
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	41
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	40
Suicide prevention research is crucial to achieving health equity for people with HIV	40
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl	40
Healing the stigma of HIV/AIDS	39
Connie Norman: a warm tribute to a forgotten AIDS activist	37
Eliminating HIV in the UK among men who have sex with men	37
Patterns of post-partum HIV care engagement	37
Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa	36
An eventful conference	35
PEPFAR: promises and pitfalls	35
Use of WHO paediatric weight-band dosing in drug labels	34
Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities	34
HIV incidence and impact of interventions among female sex workers and their clients in the Middle East and north Africa: a modelling study	34
Advancing the prevention and treatment of HIV in children: priorities for research and development	31
Living with COVID-19 and preparing for future pandemics: revisiting lessons from the HIV pandemic	31
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B	31
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial	31
HIV self-testing: from availability to strategic deployment	31
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and th	31
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study	31
Lesotho's progress towards UNAIDS 95-95-95 targets from 2016 to 2020: comparison of Population-based HIV Impact Assessments	30
Preventing sexually transmitted infections in the age of PrEP	30
How can Africa sustain its HIV response amid US aid cuts?	30
Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis	29
Addressing partner violence to end infant HIV infection	28
Reduction of HIV reservoir after stem cell transplantation	28
Thank you to The Lancet HIV's statistical and peer reviewers in 2023	28
HIV-free generation within reach for Botswana	28
Can treatment-as-prevention and PrEP reduce HIV incidence?	28
Metabolic implications and safety of dolutegravir use in pregnancy	27
Strengthening measurement and performance of HIV prevention programmes	27
Intersectional climate justice, health equity, and HIV	26
Implementation of PrEP in Latin America	25
Highlights from the 25th International AIDS Conference	25

Coffee with IAS President Beatriz Grinsztejn	24
Closing the gap to UNAIDS 95-95-95: Lesotho's success story	24
Second-line HIV treatments for adults in LMICs	24
Effects of self-testing on HIV outcomes in west Africa	24
No woman left behind: achieving cervical cancer elimination among women living with HIV	23
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study	23
Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study	23
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label,	23
The HIV care continuum for sexually active transgender women in three metropolitan municipalities in South Africa: findings from a biobehavioural survey 2018–19	23
Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cros	22
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions	22
Crucial need for improved pharmacovigilance in pregnancy	22
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa	22
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study	22
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial	22
Breast cancer survival in women living with HIV	21
Can COVID-19 changes reduce stigma in African HIV clinics?	21
Need for clear inclusion criteria in reviews of antiretroviral treatments	21
Treatment of HIV and HBV coinfection	21
The HIV vaccine quest: ethical and implementation challenges	21
Point-of-care testing to achieve paediatric 95-95-95 targets	20
Trends in suicide mortality among people with HIV after diagnosis during 2012–18: a retrospective, national cohort study in China	20
Integrase inhibitors hand us a new HIV clinical puzzle	20
Complex response to HIV and tuberculosis in South Sudan	20
Making PrEP easy	19
Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort	19
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities	19
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex w	18
Dolutegravir drug-resistance monitoring in Africa	18
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	18
Adolescent retention in HIV care within differentiated service-delivery models in sub-Saharan Africa	18
Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study	18
Paying tribute to a generation devastated by HIV/AIDS	17
Race, migration, and sexuality in focus	17
HERO—providing support for those engaged in chemsex	17
Realising long-acting ART as first-line treatment	16
HIV burden and correlates of infection among transfeminine people and cisgender men who have sex with men in Nairobi, Kenya: an observational study	16
HIV treatment in Russia on the brink of crisis	16
Long-acting PrEP for adolescent girls and young women	16
Thank you to The Lancet HIV's clinical and statistical peer reviewers in 2021	16
A new index to guide global drug policies	16
Non-communicable diseases in older people living with HIV in four African countries: a cohort study	16
Critical illness due to infection in people living with HIV	15
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study	14
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study	14
Inherited fear: 40 years of HIV/AIDS in the UK	14
Improving outcomes for children in families with HIV	14
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV	14
Initiation and continued use of oral pre-exposure prophylaxis among pregnant and postpartum women in South Africa (PrEP-PP): a demonstration cohort study	14
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study	14
HIV-related CNS infections: translating DREAMM into reality	14
Epidemiology of severe COVID-19 from South Africa	14
Unified health surveys for integrated health systems	14
Ending HIV in Chicago by 2030	14
Zvandiri—when medicines alone are not enough	14
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	13
Increased risk of mental illness in people with HIV	13
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data	13
HIV viral suppression is key to healthy longevity	12
A career dedicated to public service	12
Forgiveness of an intermittent HIV treatment strategy	11
PEPFAR reauthorisation hangs in the balance	11
Response to Thailand's commitment to support community-led HIV services	11
PrEP for men who have sex with men in Africa	11
UNAIDS strategy aligns HIV priorities with development goals	11
Correction to Lancet HIV 2023; 10: e424–26	11
Tajikistan faces a crucial moment in HIV/AIDS response	11
Immunological and virological findings in a patient with exceptional post-treatment control: a case report	11
Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study	11
Expanding options of child-friendly, single-tablet regimens for young children with HIV	11
Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study	11
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration	11
Outdated attitudes to HIV must change	11
Putting people first in communication about HIV	11
Equitable access to PrEP is essential to reap its benefits	10
UK and US militaries update HIV policies	10
Screening for chlamydia and incidence of symptomatic infections	10
Expansion of PrEP and PEP services in China	10
Long-acting PrEP: new opportunities with some drawbacks	10
Home delivery of ART: could this be a reality in South Africa?	10

Africa and AIDS: still much work to be done	10
COVID-19 antivirals must not affect HIV drug supply	10
HIV/AIDS cast a dark shadow on 1980s London gay culture	10
Thank you to The Lancet HIV's statistical and peer reviewers in 2022	10
Real-world safety of pre-exposure prophylaxis for HIV	10
Where does doravirine fit in current antiretroviral therapy?	10
Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis	10
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study	9
Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharm	9
Mexican perspective on the Mosaico HIV vaccine trial	9
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial	9
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort	9
Reassessing oral lead-in for injectable long-acting HIV therapy	9
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies	9
What future for HIV vaccines?	9
Ending AIDS as a public health threat: the imperative for clear messaging on U=U, viral suppression, and zero risk	9
Defining principles for a choice-based approach to HIV prevention	9
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level p	8
Mental health needs of adolescents with HIV in Africa	8
It is time to act on ageing	8
Drug legislation may be key to ending HIV epidemic	8
Legislation threat to services for LGBTQ+ people in Georgia	8
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administere	8
A community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho (Early Morning Star): a cluster-randomised, controlled trial	8
COP27 Climate Change Conference: urgent action needed for Africa and the world	8
So many harms, so little benefit: a global review of the history and harms of HIV criminalisation	8
The urgent need for opioid agonist treatment in Russia	8
Low-cost point-of-care urine test to enhance PrEP adherence	8
Association of life-course events with predictors of HIV risk behaviour and HIV acquisition in Manicaland, Zimbabwe: a longitudinal analysis of a population cohort	8
Dolutegravir dosing with rifampicin	8
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial	8
Use of mobile phone data in HIV epidemic control	8
HIV incidence trends in Africa: young women at highest risk	8
Documenting Brazil's battle with HIV/AIDS	8